H. Lundbeck A/S-Product Pipeline Review-2015

H. Lundbeck A/S-Product Pipeline Review-2015

  • Products Id :- GMDHC07001CDB
  • |
  • Pages: 71
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

H. Lundbeck A/S-Product Pipeline Review-2015


Global Markets Direct's, 'H. Lundbeck A/S-Product Pipeline Review-2015', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of H. Lundbeck A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of H. Lundbeck A/S including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of H. Lundbeck A/S's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the H. Lundbeck A/S's pipeline products

Reasons To Buy

Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of H. Lundbeck A/S in its therapy areas of focus

Identify new drug targets and therapeutic classes in the H. Lundbeck A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of H. Lundbeck A/S and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of H. Lundbeck A/S

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of H. Lundbeck A/S and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

H. Lundbeck A/S Snapshot 6

H. Lundbeck A/S Overview 6

Key Information 6

Key Facts 6

H. Lundbeck A/S-Research and Development Overview 7

Key Therapeutic Areas 7

H. Lundbeck A/S-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

H. Lundbeck A/S-Pipeline Products Glance 16

H. Lundbeck A/S-Late Stage Pipeline Products 16

Filing rejected/Withdrawn Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

H. Lundbeck A/S-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

H. Lundbeck A/S-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

H. Lundbeck A/S-Drug Profiles 22

carbamazepine 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

clobazam 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

droxidopa 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

idalopirdine 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

vortioxetine hydrobromide 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

LuAF-11167 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

LUAF-20513 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

LuAF-35700 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

tedatioxetine 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

KW-6356 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

LUAF-64280 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

AF-40431 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Inhibit LRRK-2 for Parkinson's Disease 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

H. Lundbeck A/S-Pipeline Analysis 42

H. Lundbeck A/S-Pipeline Products by Target 42

H. Lundbeck A/S-Pipeline Products by Route of Administration 45

H. Lundbeck A/S-Pipeline Products by Molecule Type 46

H. Lundbeck A/S-Pipeline Products by Mechanism of Action 47

H. Lundbeck A/S-Recent Pipeline Updates 49

H. Lundbeck A/S-Dormant Projects 60

H. Lundbeck A/S-Discontinued Pipeline Products 61

Discontinued Pipeline Product Profiles 61

gaboxadol 61

LuAA-47070 61

desmoteplase 62

idalopirdine 62

Lu-02750 62

Lu-35138 62

Lu-AA24493 62

LuAA-37096 62

LuAA-38466 63

LuAA-39959 63

LuAA-44608 63

LuAE-04621 63

ORE-10002 63

siramesine 63

tedatioxetine 64

zicronapine 64

H. Lundbeck A/S-Company Statement 65

H. Lundbeck A/S-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

H. Lundbeck A/S, Key Information 6

H. Lundbeck A/S, Key Facts 6

H. Lundbeck A/S-Pipeline by Indication, 2015 9

H. Lundbeck A/S-Pipeline by Stage of Development, 2015 10

H. Lundbeck A/S-Monotherapy Products in Pipeline, 2015 11

H. Lundbeck A/S-Partnered Products in Pipeline, 2015 12

H. Lundbeck A/S-Partnered Products/ Combination Treatment Modalities, 2015 13

H. Lundbeck A/S-Out-Licensed Products in Pipeline, 2015 14

H. Lundbeck A/S-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

H. Lundbeck A/S-Filing rejected/Withdrawn, 2015 16

H. Lundbeck A/S-Phase III, 2015 17

H. Lundbeck A/S-Phase II, 2015 18

H. Lundbeck A/S-Phase I, 2015 19

H. Lundbeck A/S-Preclinical, 2015 20

H. Lundbeck A/S-Discovery, 2015 21

H. Lundbeck A/S-Pipeline by Target, 2015 43

H. Lundbeck A/S-Pipeline by Route of Administration, 2015 45

H. Lundbeck A/S-Pipeline by Molecule Type, 2015 46

H. Lundbeck A/S-Pipeline Products by Mechanism of Action, 2015 48

H. Lundbeck A/S-Recent Pipeline Updates, 2015 49

H. Lundbeck A/S-Dormant Developmental Projects,2015 60

H. Lundbeck A/S-Discontinued Pipeline Products, 2015 61

H. Lundbeck A/S, Subsidiaries 66

List of Figures

H. Lundbeck A/S-Pipeline by Top 10 Indication, 2015 8

H. Lundbeck A/S-Pipeline by Stage of Development, 2015 10

H. Lundbeck A/S-Monotherapy Products in Pipeline, 2015 11

H. Lundbeck A/S-Partnered Products in Pipeline, 2015 12

H. Lundbeck A/S-Pipeline by Top 10 Target, 2015 42

H. Lundbeck A/S-Pipeline by Top 10 Route of Administration, 2015 45

H. Lundbeck A/S-Pipeline by Top 10 Molecule Type, 2015 46

H. Lundbeck A/S-Pipeline Products by Top 10 Mechanism of Action, 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of H. Lundbeck A/S; H. Lundbeck A/S - Key Therapeutics; H. Lundbeck A/S - Pipeline Overview and Promising Molecules; H. Lundbeck A/S - News; H. Lundbeck A/S - Latest Updates; H. Lundbeck A/S - Pipeline; H. Lundbeck A/S - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 99315
Site License
USD 3000 INR 198630
Corporate User License
USD 4500 INR 297945



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com